IN VITRO ANTI-INFLAMMATORY ACTIVITY TEST OF TINOCRISPOSIDE AND FREEZE-DRIED AQUEOUS EXTRACT OF TINOSPORA CRISPA STEMS ON HUMAN RED BLOOD CELL BY INCREASING MEMBRANE STABILITY EXPERIMENT

ADEK ZAMRUD ADNAN; FITHRIANI ARMIN; IKHWAN RESMALA SUDJI; MEDIOLA DWI NOVIDA; DEWI IMELDA ROESMA; HANA AFIFAH ALI; ANNISA FAUZANA

doi:10.22159/ajpcr.2019.v12i5.30690

Authors

ADEK ZAMRUD ADNAN Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Andalas University, Padang, Indonesia.
FITHRIANI ARMIN Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Andalas University, Padang, Indonesia.
IKHWAN RESMALA SUDJI Department of Biomedical, Medical Faculty of Andalas University, Padang, Indonesia.
MEDIOLA DWI NOVIDA Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Andalas University, Padang, Indonesia.
DEWI IMELDA ROESMA Department of Biology, Andalas University, Padang, Indonesia.
HANA AFIFAH ALI Department of Biology, Andalas University, Padang, Indonesia.
ANNISA FAUZANA Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Andalas University, Padang, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2019.v12i5.30690

Keywords:

Anti-inflammatory, hemolytic, human red blood cell, membrane stabilization, tinocrisposide, Tinospora crispa

Abstract

Objective: This study was aimed to evaluate the anti-inflammatory effect of isolated tinocrisposide and freeze-dried aqueous extract of Tinospora crispa stems on human red blood cell (HRBC) by increasing membrane stability in vitro models.

Methods: Anti-inflammatory effect of tinocrisposide and FDAETCS was evaluated by in vitro HRBC membrane stabilization method. The study was separated into two steps which were a hemolytic and a membrane stabilization experiment. The hemoglobin that was released throughout the damaged erythrocytes membrane was then quantified at the wavelength of (λ) 560 nm.

Results: The hemoglobin in the HBRC supernatant that treated with tinocrisposide at concentration of 100, 200, 400, 600, 800, and 1000 μg/ml showed an absorbance at λ 560 nm of 0.060, 0.061, 0.071, 0.072, 0.075, and 0.0793, respectively, and the calculated hemolysis percentage was 0.032, 0.097, 1.203, 1.236, 1.641, and 2.079%, respectively. We found a linear correlation between concentration and hemolytic activity of tinocrisposide, with regression equation, y=0.0023x−0.1312 (r=0.929). Meanwhile, the HBRC supernatant that treated with FDAETCS at concentration of 100, 200, 400, 600, and 800 μg/ml showed an absorbance at λ 560 nm of 0.063, 0.064, 0.066, 0.067, and 0.077, respectively, and revealed the hemolytic percentage of 0.347, 0.473, 0.693, 0.992, and 1.896%, respectively. It also gave a linear correlation between FDAETCS concentration and hemolytic activity percentage, with regression equation, y=0.002x+0.0222 (r=0.895). Moreover, in HRBC membrane stability experiment, tinocrisposide concentration of 100, 200, 400, 800, and 1000 μg/ml gave absorbance at λ 560 nm of 0.818, 0.808, 0.798, 0.789, 0.773, and 0.761, respectively, and calculated HRBC membrane stabilization activity as much as 5.437, 6.533, 7.707, 8.748, 10.597, and 12.100%, respectively. Meanwhile, the positive control ibuprofen 25 μg/ml only exerted the membrane stability of 5.620%. It was found a linear correlation between tinocrisposide concentration and membrane stability percentage, with the regression equation, y=0.0072x+4.8312 (r=0.9932). Treated FDAETCS in the concentration of 100, 200, 400, and 800 μg/ml gave the absorbance at λ 560 nm of 0.802, 794, 0.777, 0.791, and 0.792, with stability membrane percentage of 7.283, 8.208, 10.944, 8.555, and 8.401%, respectively. It can be seen that the FDAETCS concentrations and its hemolytic percentage showed a parabolic relationship, which gave a maximum at a concentration of the extract of 400 mg/ml with membrane stabilizing of 10.944%.

Conclusion: It can be concluded that tinocrisposide and FDAETCS have an anti-inflammatory activity by increase the membrane stability of lysosome cell that has equal physiological properties with erythrocytes membrane cell and it has no hemolytic activity.

Downloads

Download data is not yet available.

Author Biography

ADEK ZAMRUD ADNAN, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Andalas University, Padang, Indonesia.

Professor of Faculty of Pharmacy of Andalas University Padang Indonesia

References

Dweck AC, Cavin JP. Andawali (Tinospora crispa): A review. Front Pharmacol 2006;7:33-9.

Abu MN, Mohd Salleh AM, Mohd Radzman NH. Insulin sensitivity enhancement of the mixture of Tinospora crispa and gelam (Melaleuca cajuputi) honey and its antiproliferative activity on hepatocellular carcinoma, HepG2: A preliminary study. J Med Res Dev 2013;2:48-54.

Zulkhairi A Jr., Abdah MA, Kamal NH, Nursakinah I, Moklas MA, Hasnah B, et al. Biological properties of Tinospora crispa (Akar Patawali) and its antiproliferative activities on selected human cancer cell lines. Malays J Nutr 2008;14:173-87.

Sulaiman MR, Zakaria ZA, Lihan R. Antinociceptive and antiinflamatory activities of Tinospora crispa in various animal models. Int J Topical Med 2008;3:66-9.

Yokozawa T, Wang TS, Chen CP, Hattori M. Inhibition of nitric oxide release by an aqueous extract of Tinospora tuberculata. Phytother Res 2000;14:51-3.

Zakaria ZA, Mat Jais AM, Henie EF, Zaiton H, Somchit MN, Sulaiman MR, et al. The in vitro antibacterial activity of Tinospora crispa extracts. J Biol Sci 2006;6:398-401.

Kongkathip N, Dhumma-upakorn P, Kongkathip B, Chawananoraset K, Sangchomkaeo P, Hatthakitpanichakul S. Study on cardiac contractility of cycloeucalenol and cycloeucalenone isolated from Tinospora crispa. J Ethnopharmacol 2002;83:95-9.

Noor H, Ashcroft SJ. Pharmacological characterisation of the antihyperglycaemic properties of Tinospora crispa extract. J Ethnopharmacol 1998;62:7-13.

Pachaly P, Adnan AZ. Tinocrisposide, a new furanoditerpene glycoside from Tinospora crispa. Arch Pharm (Weinheim) 1992;325:705-8.

Adnan AZ, Taher M, Afriani T, Fauzana A, Roesma DI, Putra AE. Anti-inflamatory activity of tinocrisposide by inhibiting nitric oxide production in lipopolysaccharides-stimulated raw 264.7 cells. Asian J Pharm Clin Res 2018;11:149-53.

Chandra S, Juvekar AR. In vitro anti-inflammatory activity of syringic acid. Int J Pharm Pharm Sci 2018;11:71-3.

Shamsi TN, Parveen R, Sajida A, Ahmad A, Fatima S. Assessing the therapeutic role of Joshanda: Phytochemical, antioxidant, anti-inflammatory and antimicrobial activities. Int J Pharm Pharm Sci 2018;10:122-8.

Nathan C. Points of control in inflammation. Nature 2002;420:846-52.

Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7.

Chen C. COX-2’s new role in inflammation. Nat Chem Biol 2010;6:401 2.

Katzung BG. Basic and Clinical Pharmacology: 10th ed. San Francisco, USA: McGraw Hill Lange; 2006.

Katzung BG. Basic and Clinical Pharmacology. 12th ed. New York: McGraw Hill Lange; 2012.

Kumar V, Bhat ZA, Kumar D, Khan NA, Chashoo IA. Evaluation of anti-inflammatory potential of leaf extracts of Skimmia anquetilia. Asian Pac J Trop Biomed 2012;2:627-30.

Minegishi T, Nakamura K, Yamashita S, Ikeda S, Kogure K. Regulation of human luteinizing hormone receptor in the ovary. Reprod Med Biol 2008;7:11-6.

Saleem TK, Azeem AK, Dilip C, Sankar C, Prasanth NV, Duraisami R. Anti-inflammatory activity of the leaf extacts of Gendarussa vulgaris nees. Asian Pac J Trop Biomed 2011;1:147-9.

Sudji IR, Subburaj Y, Frenkel N, García-Sáez AJ, Wink M. Membrane disintegration caused by the steroid saponin digitonin is related to the presence of cholesterol. Molecules 2015;20:20146-60.

Hipol RL, Cariaga MF, Hipol RM. Anti-inflammatory activities of the aqueous extract of the stem of Tinospora crispa (Family Menispermaceae). J Nat Stud 2012;11:88-95.

Kumar P, Arora S, Yadav YC. Anti-inflammatory activity of coumarin and steroidal fractions from leaves of Moringa oleifera. Int J Drug Discov Med Res 2012;1:22-5.

Bakkali F, Averbeck S, Averbeck D, Idaomar M. Biological effects of essential oils – a review. Food Chem Toxicol 2008;46:446-75.

Serhan CN. System approach to inflammation resolution: Identification of novel anti-inflammatory and pro-resolving mediators. J Thromb Haemost 2009;7 Suppl 1:44-8.